您的当前位置:首页 > 行业数据 > PCSK9药物研发格局(筛选全球最高研发阶段进入III期的活跃管线)
图片属性
图片格式:PNG 图片大小:1081KB 图片尺寸:2303*2104
同报告图片
 / 4
PCSK9药物研发格局(筛选全球最高研发阶段进入III期的活跃管线)_第1页
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
PCSK9药物研发格局(筛选全球最高研发阶段进入III期的活跃管线)_第2页
PCSK9药物研发格局(筛选全球最高研发阶段进入III期的活跃管线)_第3页
PCSK9药物研发格局(筛选全球最高研发阶段进入III期的活跃管线)_第4页
PCSK9药物研发格局(筛选全球最高研发阶段进入III期的活跃管线)_第5页
所属报告: 医药行业代谢领域系列报告——降脂药物研发:BIC研发导向中国工程师红利优势领域-260527(19页).pdf
打包全文图表

相关数据

客服
商务合作
小程序
服务号
折叠